Finding the best shares to buy on the ASX requires more than just scanning a screener or chasing whatever is up this week. We focus on companies with strong competitive positioning, visible earnings growth, and a catalyst to drive the share price higher over the next 12 months. Every stock on this list has been through a full research process covering financials, industry dynamics, valuation, and management quality.
We update this page regularly as new research is published. The five stocks below represent our most recent work, ordered from newest to oldest. Each summary covers the key points of the investment case, with a link to the full write-up for those who want the detail.
Last updated 26 June 2026.
| Stock | Rating | Price Target | Last Price | Upside | Div Yield |
| ResMed Inc (ASX: RMD) | Buy | A$46.70 | A$28.94 | 61.4% | ~1.3% |
| Collins Foods Ltd (ASX: CKF) | Buy | A$10.70 | A$8.32 | 28.6% | ~3.1% |
| Worley Ltd (ASX: WOR) | Buy | A$15.50 | A$10.83 | 43.1% | 4.1% |
| WEB Travel Group (ASX: WEB) | Buy | A$4.70 | A$2.98 | 57.7% | |
| Aristocrat Leisure Ltd (ASX: ALL) | Buy | A$61.00 | A$58.69 | 3.9% | ~2.0% |
Our Top 5 Stocks To Buy Right Now on the ASX
Table of Contents
ResMed Inc (ASX: RMD)
Buy, 12-month price target A$46.70 (~75% upside), ~1.3% forward dividend yield. Price target and upside based on prices at time of publication.
ResMed is the world’s largest maker of devices and masks for obstructive sleep apnea, dual-listed on the ASX and the New York Stock Exchange with the number one global share position in its core market. The stock has drifted lower over the past two months even as the operating story has improved, leaving it on around 16.9 times forward earnings, roughly two turns below its global medtech peers and six turns below its ASX healthcare peers. Two worries explain the discount, and both look more like sentiment than substance. The first is the fear that GLP-1 weight-loss drugs shrink the CPAP market, yet the patient-flow data shows GLP-1 patients are more likely to start and stay on therapy, not less. The second is the return of Philips to the United States market, which is well understood and already priced.
Underneath the noise, a stack of new growth levers is only now starting to scale. The Noctrix acquisition opens the restless legs market, the AirCurve 11 ventilators move ResMed into chronic respiratory care, the AirMini and a new partnership with Oura widen the cash-pay and screening funnel, and a digital service for the United Kingdom National Health Service adds an offshore revenue line. Layer gross margin expansion onto high single-digit revenue growth and the result is earnings per share growing in the mid-teens out to FY28. The 12-month target of A$46.70 implies around 75 per cent upside, and with a net cash balance sheet and a return on capital in the mid-twenties, the risk and reward is skewed upward. Read the full article on ResMed here.
Collins Foods Ltd (ASX: CKF)
Buy, 12-month price target A$10.70 (~29% upside), ~3.1% forward dividend yield. Price target and upside based on prices at time of publication.
Collins Foods is the largest KFC franchisee in Australia, with more than 80 per cent of its network concentrated in Queensland and Western Australia. Those two states are running materially ahead of the national average on the metrics that matter for discretionary spending. Brisbane and Perth dwelling prices rose approximately 18 per cent and 26 per cent over the past year, population growth in Queensland and WA outpaces the national rate, and Queensland heads into a sustained infrastructure investment cycle as preparations for the 2032 Brisbane Olympics begin. These structural tailwinds give Collins an exposure advantage that peers with Sydney or Melbourne-weighted footprints do not share.
The principal headwind is labour. A 4.75 per cent minimum wage increase, layered on a multi-year phase-in of higher youth wage rates, is forecast to compress KFC Australia EBITDA margins by around 35 basis points in FY27. The key offset is a self-service kiosk rollout reaching 100 per cent of the KFC Australia network by October 2026, up from 70 per cent in October 2025. Kiosks typically lift in-store sales by up to 20 per cent while reducing front-counter labour, giving management a direct two-way lever on the same cost line the wage increases are squeezing. The stock trades at roughly a 20 per cent discount to its historical next-twelve-month price-to-earnings multiple, pricing in the wage and consumer headwinds while the state-exposure and kiosk tailwinds are not yet reflected in the multiple. Read the full article on Collins Foods here.
Worley Ltd (ASX: WOR)
Buy, 12-month price target A$15.50 (27.2% upside), 4.1% forward dividend yield. Price target and upside based on prices at time of publication.
Worley is an Australian-headquartered global engineering and project services firm to the energy, chemicals and resources sectors, with around 50,000 staff across 50 countries. Management used its May 2026 Investor Day to set a medium-term target of double-digit EBITA growth through to FY30, anchored on two strategic shifts. The first is expanding into adjacent complex infrastructure markets like data centres, large-scale power, nuclear and industrial water. The second is capturing more of the project life cycle by moving from engineering-led delivery into procurement and construction.
The wider thesis is supported by a structurally larger addressable market. Cumulative 2026 to 2030 capex across the adjacent infrastructure segments Worley is targeting is 15 to 20 times larger than the existing core, with data centres alone representing approximately US$144 billion per year of global capex against a 20 to 30 per cent compound growth rate. The deeper thesis carries a near-term margin trade-off, but the A$125 million cost-out programme is sized to fully reverse the mix-shift dilution back to a 9.5 per cent group EBITA margin.
The stock trades on 10.2 times next twelve months EV/EBIT, a 21 per cent discount to its 5-year average and 14 per cent below global peers, against a 5-year average premium to peers of 4 per cent. With approximately 27 per cent upside to the institutional price target and a forecast dividend yield stepping from 4.1 per cent in FY26 to 5.1 per cent in FY28, the entry point looks attractive for investors with a multi-year horizon. Read the full article on Worley here.
WEB Travel Group (ASX: WEB)
Buy, 12-month price target A$4.70 (110.8% upside). Price target and upside based on prices at time of publication.
WEB Travel Group operates WebBeds, the world’s second-largest B2B accommodation wholesaler behind Expedia’s B2B segment. The platform connects hotels with travel providers including OTAs, traditional agents, airlines and tour operators. WEB was demerged from Webjet Limited in 2024, separating the B2B wholesale operations from the consumer-facing business (now Webjet Group, ASX: WJL). Market cap of approximately A$813 million with a 30 June fiscal year end.
The hotel bed wholesaling sector is growing at double-digit rates across every major player. WEB posted 17 per cent constant-currency TTV growth in 1H26, HBX is guiding 11 to 17 per cent, and Expedia B2B grew gross bookings 22 per cent in 1Q26. Near-term headwinds from the Middle East conflict and a stronger Australian dollar have compressed estimates by 6 to 18 per cent, but the Middle East represents less than 9 per cent of group TTV and the impact is cyclical rather than structural. Americas share gains continue to come through in results.
At 9 times forward earnings against a 16 times historical average, the market is pricing in a permanent impairment that the numbers do not support. The target of A$4.70 is derived from a blend of FY27 EV/EBITDA fundamental value (85% weight at 9.0x) and theoretical M&A (15% weight at 17.0x). The risk-reward at current levels looks compelling for investors willing to look through the near-term noise. Read the full article on WEB Travel Group here.
Aristocrat Leisure Ltd (ASX: ALL)
Buy, 12-month price target A$61.00 (33.0% upside), ~2.0% forward dividend yield. Price target and upside based on prices at time of publication.
Aristocrat Leisure is the global leader in land-based gaming content and cabinets, with a market share above 40 per cent in key jurisdictions. The company also operates Product Madness (social casino) and a growing real-money iGaming and iLottery segment. Listed on the ASX since 1996 with a September fiscal year end.
We rate Aristocrat a Buy with a 12-month price target of A$61.00, implying 33 per cent upside from current levels. The 1H26 result showed Gaming revenue growing 5 per cent on a normalised basis, with net machine adds tracking to the upper end of management guidance. The Board has lifted the on-market buyback to A$1 billion for FY26 and the interim dividend was increased to 50 cents per share, accelerating capital returns well beyond the prior pace.
On consensus estimates, the forward P/E compresses from 27 times today to roughly 14 times by FY28 as earnings growth catches up. This does not require multiple expansion, just delivery on the existing growth trajectory. For a business with this quality of franchise and capital allocation discipline, 14 times forward earnings represents a meaningful discount to global gaming peers. Read the full article on Aristocrat Leisure here.
How We Pick Stocks for This List
Our selection process draws on institutional-grade research combined with our own analysis of each company’s competitive positioning, earnings trajectory, and valuation. We focus on ASX-listed businesses with clear catalysts, strong or improving returns on capital, and management teams with a track record of execution. Every stock on this list carries a Buy rating with a defined price target and investment thesis.
We are not trying to pick the next speculative runner. The companies featured here are profitable, have established market positions, and offer a risk-reward profile that we think makes sense for investors looking to build long-term wealth through Australian equities. We refresh this list as new research is completed, typically every few weeks.
If you would like to discuss any of these names or how they might fit within your portfolio, request a callback or call us on 1300 889 603.
